Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza; Caitrin Fretham; Stephanie J. Lee; Mukta Arora; Janet Brunner; Saurabh Chhabra; Steven Devine; Mary Eapen; Mehdi Hamadani; Parameswaran Hari; Marcelo C. Pasquini; Waleska Perez; Rachel A. Phelan; Marcie L. Riches; J. Douglas Rizzo; Wael Saber; Bronwen E. Shaw; Stephen R. Spellman; Patricia Steinert; Daniel J. Weisdorf; Mary M. Horowitz

doi:10.1016/j.bbmt.2020.04.013

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza, Caitrin Fretham, Stephanie J. Lee, Mukta Arora, Janet Brunner, Saurabh Chhabra, Steven Devine, Mary Eapen, Mehdi Hamadani, Parameswaran Hari, Marcelo C. Pasquini, Waleska Perez, Rachel A. Phelan, Marcie L. Riches, J. Douglas Rizzo, Wael Saber, Bronwen E. Shaw, Stephen R. Spellman, Patricia Steinert, Daniel J. WeisdorfMary M. Horowitz

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

316 Scopus citations

Abstract

Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.

Original language	English (US)
Pages (from-to)	e177-e182
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	8
DOIs	https://doi.org/10.1016/j.bbmt.2020.04.013
State	Published - Aug 2020

Bibliographical note

Publisher Copyright:
© 2020 American Society for Transplantation and Cellular Therapy

Keywords

Activity
Hematopoietic cell transplantation
Summary slides

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.bbmt.2020.04.013

OpenUrl availability

Full text

Cite this

D'Souza, A., Fretham, C., Lee, S. J., Arora, M., Brunner, J., Chhabra, S., Devine, S., Eapen, M., Hamadani, M., Hari, P., Pasquini, M. C., Perez, W., Phelan, R. A., Riches, M. L., Rizzo, J. D., Saber, W., Shaw, B. E., Spellman, S. R., Steinert, P., ... Horowitz, M. M. (2020). Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biology of Blood and Marrow Transplantation, 26(8), e177-e182. https://doi.org/10.1016/j.bbmt.2020.04.013

D'Souza, A, Fretham, C, Lee, SJ, Arora, M, Brunner, J, Chhabra, S, Devine, S, Eapen, M, Hamadani, M, Hari, P, Pasquini, MC, Perez, W, Phelan, RA, Riches, ML, Rizzo, JD, Saber, W, Shaw, BE, Spellman, SR, Steinert, P, Weisdorf, DJ & Horowitz, MM 2020, 'Current Use of and Trends in Hematopoietic Cell Transplantation in the United States', Biology of Blood and Marrow Transplantation, vol. 26, no. 8, pp. e177-e182. https://doi.org/10.1016/j.bbmt.2020.04.013

@article{245b5073078546d7bb5aa05c016c176c,

title = "Current Use of and Trends in Hematopoietic Cell Transplantation in the United States",

abstract = "Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.",

keywords = "Activity, Hematopoietic cell transplantation, Summary slides",

author = "Anita D'Souza and Caitrin Fretham and Lee, {Stephanie J.} and Mukta Arora and Janet Brunner and Saurabh Chhabra and Steven Devine and Mary Eapen and Mehdi Hamadani and Parameswaran Hari and Pasquini, {Marcelo C.} and Waleska Perez and Phelan, {Rachel A.} and Riches, {Marcie L.} and Rizzo, {J. Douglas} and Wael Saber and Shaw, {Bronwen E.} and Spellman, {Stephen R.} and Patricia Steinert and Weisdorf, {Daniel J.} and Horowitz, {Mary M.}",

note = "Publisher Copyright: {\textcopyright} 2020 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = aug,

doi = "10.1016/j.bbmt.2020.04.013",

language = "English (US)",

volume = "26",

pages = "e177--e182",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

AU - D'Souza, Anita

AU - Fretham, Caitrin

AU - Lee, Stephanie J.

AU - Arora, Mukta

AU - Brunner, Janet

AU - Chhabra, Saurabh

AU - Devine, Steven

AU - Eapen, Mary

AU - Hamadani, Mehdi

AU - Hari, Parameswaran

AU - Pasquini, Marcelo C.

AU - Perez, Waleska

AU - Phelan, Rachel A.

AU - Riches, Marcie L.

AU - Rizzo, J. Douglas

AU - Saber, Wael

AU - Shaw, Bronwen E.

AU - Spellman, Stephen R.

AU - Steinert, Patricia

AU - Weisdorf, Daniel J.

AU - Horowitz, Mary M.

PY - 2020/8

Y1 - 2020/8

N2 - Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.

AB - Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.

KW - Activity

KW - Hematopoietic cell transplantation

KW - Summary slides

UR - http://www.scopus.com/inward/record.url?scp=85085969206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085969206&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2020.04.013

DO - 10.1016/j.bbmt.2020.04.013

M3 - Review article

C2 - 32438042

AN - SCOPUS:85085969206

SN - 1083-8791

VL - 26

SP - e177-e182

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 8

ER -

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this